DE60011761D1 - Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen - Google Patents
Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellenInfo
- Publication number
- DE60011761D1 DE60011761D1 DE60011761T DE60011761T DE60011761D1 DE 60011761 D1 DE60011761 D1 DE 60011761D1 DE 60011761 T DE60011761 T DE 60011761T DE 60011761 T DE60011761 T DE 60011761T DE 60011761 D1 DE60011761 D1 DE 60011761D1
- Authority
- DE
- Germany
- Prior art keywords
- arpe
- cell line
- cells
- administrating
- platform cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US543119 | 1990-06-22 | ||
US12792699P | 1999-04-06 | 1999-04-06 | |
US127926P | 1999-04-06 | ||
US09/543,119 US6361771B1 (en) | 1999-04-06 | 2000-04-05 | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
PCT/US2000/009150 WO2000060051A2 (en) | 1999-04-06 | 2000-04-06 | Arpe-19 as a platform cell line for encapsulated cell-based delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60011761D1 true DE60011761D1 (de) | 2004-07-29 |
DE60011761T2 DE60011761T2 (de) | 2005-08-04 |
Family
ID=26826092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60011761T Expired - Lifetime DE60011761T2 (de) | 1999-04-06 | 2000-04-06 | Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen |
Country Status (12)
Country | Link |
---|---|
US (2) | US6361771B1 (de) |
EP (1) | EP1171573B1 (de) |
JP (2) | JP4954374B2 (de) |
AT (1) | ATE269715T1 (de) |
AU (1) | AU773387B2 (de) |
BR (1) | BR0009562A (de) |
CA (1) | CA2365532C (de) |
DE (1) | DE60011761T2 (de) |
DK (1) | DK1171573T3 (de) |
ES (1) | ES2219335T3 (de) |
NO (1) | NO20014856D0 (de) |
WO (1) | WO2000060051A2 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878544B2 (en) * | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
US20070071734A1 (en) * | 1999-04-06 | 2007-03-29 | Weng Tao | ARPE-19 as platform cell line for encapsulated cell-based delivery |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
WO2003033016A1 (en) * | 2001-10-16 | 2003-04-24 | Jenny Phipps | Use of neurotrophic factors for treating neurodegenerative diseases and cancer |
US20040005302A1 (en) * | 2002-04-30 | 2004-01-08 | Gonzalo Hortelano | Encapsulated cells to elicit immune responses |
JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | 潤滑油組成物 |
DE602004021648D1 (de) | 2003-04-18 | 2009-07-30 | Biogen Idec Inc | Polymerkonjugiertes glycosiliertes Neublastin |
RU2005138368A (ru) * | 2003-06-10 | 2006-07-27 | ЭнЭсДЖЕНЕ А/С (DK) | Улучшенная секреция нейбластина |
US7897384B2 (en) * | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US7927599B2 (en) * | 2003-09-08 | 2011-04-19 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US8257963B2 (en) * | 2007-06-01 | 2012-09-04 | Depuy Mitek, Inc. | Chondrocyte container and method of use |
US7598059B2 (en) * | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
NZ547185A (en) | 2003-10-20 | 2009-03-31 | Nsgene As | In vivo gene therapy of parkinson's disease |
US20060239966A1 (en) * | 2003-10-20 | 2006-10-26 | Tornoee Jens | In vivo gene therapy of parkinson's disease |
CN1950397B (zh) | 2004-03-30 | 2012-05-16 | Ns基因公司 | 生长因子NsG33的治疗用途 |
DE602005022457D1 (de) * | 2004-08-19 | 2010-09-02 | Biogen Idec Inc | Neublastin-varianten |
ES2349043T3 (es) * | 2004-08-19 | 2010-12-22 | Biogen Idec Ma Inc. | Variantes de neublastina. |
US8088567B2 (en) * | 2005-04-01 | 2012-01-03 | Nsgene A/S | Human immortalised neural precursor cell line |
CA2609000C (en) * | 2005-05-17 | 2015-01-13 | Nsgene A/S | An implantable therapy system for treating a living being with an active factor |
US20080260702A1 (en) * | 2005-10-11 | 2008-10-23 | Jesper Roland Jorgensen | Treatment of Retinopathies Using Gfra3 Agonists |
JP2009513584A (ja) * | 2005-10-28 | 2009-04-02 | エヌエスゲーネ・アクティーゼルスカブ | Gdnfの送達のための移植可能な生体適合性免疫隔離ビヒクル |
AU2006332971B2 (en) * | 2005-12-30 | 2013-03-07 | Neurotech Usa, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
US20100056440A1 (en) * | 2006-03-01 | 2010-03-04 | Biogen Idec Ma Inc. | Compositions and methods for administering gdnf ligand family proteins |
ES2476253T3 (es) * | 2007-05-01 | 2014-07-14 | Biogen Idec Ma Inc. | P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado |
WO2009020964A2 (en) * | 2007-08-08 | 2009-02-12 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
US20090196854A1 (en) * | 2008-02-04 | 2009-08-06 | Kytos Biosystems S.A. | Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery |
US8075537B2 (en) * | 2008-08-15 | 2011-12-13 | Oxyband Technologies, Inc. | Multiple cell therapeutic diffusion device |
WO2010083842A2 (en) | 2009-01-23 | 2010-07-29 | Nsgene A/S | Expression of neuropeptides in mammalian cells |
AU2010206374B2 (en) * | 2009-01-23 | 2013-01-17 | Gloriana Therapeutics Sarl | Improved cell lines and their use in encapsulated cell biodelivery |
EP2421981B1 (de) * | 2009-04-23 | 2013-08-14 | Neurotech USA, Inc. | Zelllinien zur produktion von prostaglandin-f2-alpha (pgf2a) und verwendungen davon |
WO2011044216A1 (en) * | 2009-10-08 | 2011-04-14 | Neurotech Usa, Inc. | Use of pedf in an encapsulated cell-based delivery system |
WO2011053774A1 (en) | 2009-10-30 | 2011-05-05 | Alcon Research, Ltd. | Single nucleotide polymorphisms and genes associated with age-related macular degeneration |
US8808687B2 (en) | 2010-07-12 | 2014-08-19 | Mark Humayun | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
AU2011307488B2 (en) | 2010-10-01 | 2015-08-20 | Hoba Therapeutics Aps | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
KR20140091651A (ko) | 2010-12-02 | 2014-07-22 | 뉴로테크 유에스에이, 인코포레이티드. | 항-혈관 신생 항체-스캐폴드 및 가용성 수용체를 분비하는 세포주 및 이의 용도 |
US8877489B2 (en) | 2011-12-05 | 2014-11-04 | California Institute Of Technology | Ultrathin parylene-C semipermeable membranes for biomedical applications |
WO2012149468A2 (en) | 2011-04-29 | 2012-11-01 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
MX354516B (es) | 2011-10-27 | 2018-03-08 | Wellstat Ophthalmics Corp | Vectores que codifican el factor de viabilidad de conos derivado de bastones. |
US9248013B2 (en) | 2011-12-05 | 2016-02-02 | California Institute Of Technology | 3-Dimensional parylene scaffold cage |
WO2013181424A1 (en) | 2012-05-30 | 2013-12-05 | Neurotech Usa, Inc. | Cryopreserved implantable cell culture devices and uses thereof |
US20160123960A1 (en) * | 2013-06-10 | 2016-05-05 | Millennium Pharmaceuticals, Inc. | Method for preparing three-dimensional, organotypic cell cultures and uses thereof |
CA2922483A1 (en) * | 2013-09-11 | 2015-03-19 | Neurotech Usa, Inc. | Encapsulated cell therapy cartridge |
FR3014316B1 (fr) | 2013-12-10 | 2017-01-20 | Defymed | Organe bioartificiel |
EP3188712A1 (de) | 2014-09-04 | 2017-07-12 | Kemijski Institut | Zellbasierte vorrichtung zur lokalen behandlung mit therapeutischem protein |
EP3302524B1 (de) * | 2015-05-27 | 2020-09-23 | Neurotech USA, Inc. | Verwendung von eingekapselter zelltherapie zur behandlung von glaukom |
CA3156956A1 (en) | 2019-11-01 | 2021-05-06 | Neurotech Usa, Inc. | System, apparatuses, devices, and methods for packaging an analyte diffusive implantable device |
CN115697300A (zh) | 2020-04-09 | 2023-02-03 | 帝梵麦德公司 | 用于医疗装置的膜 |
EP3892259A1 (de) | 2020-04-09 | 2021-10-13 | Defymed | Membranen für medizinische vorrichtungen |
WO2022011081A1 (en) | 2020-07-09 | 2022-01-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cell lines that produce human retinoschisin proteins and uses thereof |
EP4333872A1 (de) | 2021-05-06 | 2024-03-13 | Hoba Therapeutics ApS | Vorbeugung und behandlung von chemotherapie-induzierten neuropathischen schmerzen |
WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
US5614404A (en) | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
DK0585368T3 (da) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
FR2681609B1 (fr) | 1991-09-24 | 1994-12-30 | Centre Nat Rech Scient | Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale. |
WO1994001139A1 (en) | 1992-07-13 | 1994-01-20 | Baylor College Of Medicine | Targeting somatic gene therapy to joints |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
AU688776B2 (en) | 1993-06-23 | 1998-03-19 | Brown University Research Foundation | Method and apparatus for sealing implantable, membrane encapsulation devices |
JP4098355B2 (ja) | 1993-08-12 | 2008-06-11 | ニューロテック ユーエスエー, インコーポレイテッド | 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル |
US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
US6020192A (en) * | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
US5998598A (en) | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
-
2000
- 2000-04-05 US US09/543,119 patent/US6361771B1/en not_active Expired - Lifetime
- 2000-04-06 BR BRPI0009562-1A patent/BR0009562A/pt not_active IP Right Cessation
- 2000-04-06 EP EP00923144A patent/EP1171573B1/de not_active Expired - Lifetime
- 2000-04-06 DE DE60011761T patent/DE60011761T2/de not_active Expired - Lifetime
- 2000-04-06 ES ES00923144T patent/ES2219335T3/es not_active Expired - Lifetime
- 2000-04-06 CA CA2365532A patent/CA2365532C/en not_active Expired - Lifetime
- 2000-04-06 WO PCT/US2000/009150 patent/WO2000060051A2/en active IP Right Grant
- 2000-04-06 AU AU43319/00A patent/AU773387B2/en not_active Expired
- 2000-04-06 AT AT00923144T patent/ATE269715T1/de active
- 2000-04-06 US US09/958,040 patent/US7115257B1/en not_active Expired - Lifetime
- 2000-04-06 DK DK00923144T patent/DK1171573T3/da active
- 2000-04-06 JP JP2000609543A patent/JP4954374B2/ja not_active Expired - Lifetime
-
2001
- 2001-10-05 NO NO20014856A patent/NO20014856D0/no not_active Application Discontinuation
-
2010
- 2010-11-16 JP JP2010256357A patent/JP2011074079A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2219335T3 (es) | 2004-12-01 |
US7115257B1 (en) | 2006-10-03 |
DK1171573T3 (da) | 2004-09-27 |
CA2365532A1 (en) | 2000-10-12 |
EP1171573B1 (de) | 2004-06-23 |
BR0009562A (pt) | 2007-05-29 |
WO2000060051A2 (en) | 2000-10-12 |
ATE269715T1 (de) | 2004-07-15 |
WO2000060051A3 (en) | 2002-03-28 |
EP1171573A1 (de) | 2002-01-16 |
CA2365532C (en) | 2012-11-06 |
JP4954374B2 (ja) | 2012-06-13 |
JP2003524621A (ja) | 2003-08-19 |
AU4331900A (en) | 2000-10-23 |
AU773387B2 (en) | 2004-05-27 |
WO2000060051A8 (en) | 2001-04-05 |
JP2011074079A (ja) | 2011-04-14 |
DE60011761T2 (de) | 2005-08-04 |
US6361771B1 (en) | 2002-03-26 |
NO20014856D0 (no) | 2001-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60011761D1 (de) | Arpe-19 als plattform zellinie zur verabreichung eingekapselter zellen | |
Jiang et al. | Local release of dexamethasone from macroporous scaffolds accelerates islet transplant engraftment by promotion of anti-inflammatory M2 macrophages | |
Chae et al. | Protection of insulin secreting cells from nitric oxide induced cellular damage by crosslinked hemoglobin | |
Wong et al. | Pullulan hydrogels improve mesenchymal stem cell delivery into high‐oxidative‐stress wounds | |
Kokoshis et al. | Increased resistance to Staphylococcus aureus infection and enhancement in serum lysozyme activity by glucan | |
Carrade et al. | Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions | |
FI95044B (fi) | Uudet immobilisoidut biokatalysaattorit sekä niiden valmistus ja käyttö | |
WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
AU2006201898A1 (en) | Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition | |
EP1553893A2 (de) | Implantation von verkapseltem biologischem material zur behandlung von krankheiten | |
ATE284674T1 (de) | Hybride matrizen und gemische davon | |
ATE446373T1 (de) | Sequenz-spezifische dna-rekombination in eukaryotischen zellen | |
Matsushima et al. | Bidirectional homing of Tregs between the skin and lymph nodes | |
WO2017024076A1 (en) | Cell transplantation device | |
Slavin et al. | Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation | |
CN101947312B (zh) | 一种可直接皮肤外用的mPEG-SOD纳米乳及其制备方法 | |
CN110114060A (zh) | 具有杀菌作用的制剂 | |
NO20000990D0 (no) | Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta> | |
Wee et al. | Cell surface modification by activated polyethylene glycol prevents allosensitization after islet transplantation | |
CN104224839A (zh) | 一种具有抗衰老功效的干细胞注射液及其制备方法 | |
ES2132027A1 (es) | Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante. | |
Bustos et al. | Enzyme replacement therapy in porphyrias-III: Potential use of erythrocyte ghosts as carriers of δ-aminolaevulinate dehydratase | |
Sibuea et al. | TNF-α and IL-10 as paracrine effect of encapsulated mesenchymal stem cells coating by platelet lysate | |
ATE336569T1 (de) | Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen | |
CN1340342A (zh) | 用哌啶类氮氧化物防治皮肤的氧化性损伤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: NEUROTECH S.A., PARIS, FR |
|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NEUROTECH USA, INC. (N. D. GES. D. STAATES DEL, US |